PMN
What one share of Promis Neurosciences holds
Pharmaceutical Preparations
ProMIS has in-licensed a patented technology platform with the potential to deliver a portfolio of antibody therapies, therapeutic vaccines, and other therapies derived from antibodies for neurodegenerative diseases and other misfolded protein diseases, which may include Alzheimer’s disease, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, Parkinson’s disease, progressive supranuclear palsy, corticobasal degeneration (respectively…
Promis Neurosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$8.45 |
|---|---|
| Cash and investments | $5.96 |
| Book value | $5.51 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$42.30 | $0.03 | −$40.24 | — | $19.67 |
| 2022 | — | −$60.19 | $0.01 | −$56.77 | — | −$3.93 |
| 2023 | — | −$26.87 | — | −$22.05 | — | $4.97 |
| 2024 | — | $2.63 | — | −$25.68 | — | $12.61 |
| 2025 | — | −$22.61 | — | −$16.01 | — | −$0.58 |